What is Petros Pharmaceuticals Inc's earnings per share (EPS)?

Petros Pharmaceuticals Inc (PTPI) reported diluted earnings per share of $-1.56 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Petros Pharmaceuticals Inc Financials

PTPI

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Petros Pharmaceuticals Inc (PTPI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PTPI FY2025 2026-05-13

A balance-sheet recapitalization restored liquidity, but the business still looks externally financed rather than self-funding.

FY2025’s positive net income of $1.9M did not mark a self-funded turnaround because operating cash flow was still -$6.7M and cash was replenished by $8.2M of financing. That follows a sharp balance-sheet repair from FY2024, when equity moved from -$7.5M to $2.9M and the current ratio improved from 0.4x to 2.3x, showing that recapitalization—not operating cash generation—did most of the work.

Between FY2023 and FY2024, operating losses narrowed from -$13.6M to -$4.6M even though revenue slipped, which points to a cost reset rather than a sales-led improvement. SG&A was cut sharply while gross margin stayed above 70.0%, so the operating problem became overhead absorption more than product-level economics.

The business is light on capital spending: FY2024 free cash flow of -$2.6M was almost identical to operating cash flow of -$2.6M because capex was only $25K. The financing cost of staying liquid is visible in share count expansion from 421K to 42.3M by FY2025, meaning the balance sheet improved by bringing in capital, not by the business funding itself.

Financial Health Signals

Financial health score pending refresh

We are recalculating Petros Pharmaceuticals Inc's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Piotroski F-Score Partial

3/6

Petros Pharmaceuticals Inc passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality Low Quality

-3.52x

For every $1 of reported earnings, Petros Pharmaceuticals Inc generates $-3.52 in operating cash flow (-$6.7M OCF vs $1.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-18.1x

Petros Pharmaceuticals Inc earns $-18.1 in operating income for every $1 of interest expense (-$4.6M vs $257K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

$1.9M

YoY+113.4%

Petros Pharmaceuticals Inc reported $1.9M in net income in fiscal year 2025. This represents an increase of 113.4% from the prior year.

EPS (Diluted)

$-1.56

Petros Pharmaceuticals Inc earned $-1.56 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$5.1M

YoY+198.9%

5Y CAGR-21.4%

Petros Pharmaceuticals Inc held $5.1M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

42M

Petros Pharmaceuticals Inc had 42M shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

66.7%

5Y CAGR+184.5pp

Petros Pharmaceuticals Inc's ROE was 66.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

PTPI Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	$5.1M-12.2%	$5.8M-2.8%	$6.0M-23.3%	$7.8M-18.3%	$9.6M
Cost of Revenue	N/A	$1.2M-25.7%	$1.6M-28.7%	$2.3M+43.1%	$1.6M-60.5%	$4.0M
Gross Profit	N/A	$3.9M-7.0%	$4.2M+13.2%	$3.7M-40.4%	$6.2M+12.7%	$5.5M
R&D Expenses	N/A	$2.6M+8.5%	$2.4M+38.4%	$1.7M-2.7%	$1.8M+289.1%	$460K
SG&A Expenses	$4.6M+0.3%	$4.6M-50.0%	$9.3M-24.1%	$12.2M-21.7%	$15.6M-0.5%	$15.7M
Operating Income	-$4.6M-0.3%	-$4.6M+66.0%	-$13.6M+31.6%	-$19.9M-10.3%	-$18.0M-4.4%	-$17.3M
Interest Expense	$257K-54.2%	$561K+4.6%	$536K-10.0%	$596K+61.7%	$369K-87.9%	$3.1M
Income Tax	$0	$0	$0	N/A	$0+100.0%	-$1.4M
Net Income	$1.9M+113.4%	-$14.3M-75.4%	-$8.2M+59.3%	-$20.0M-123.0%	-$9.0M+56.3%	-$20.6M
EPS (Diluted)	$-1.56	$-83.47	$-6.35+34.4%	$-9.68-17.3%	$-8.25	$-3.85

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	$725K-54.0%	$1.6M+10.9%	$1.4M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	$265K-7.8%	$287K-12.8%	$329K
Gross Profit	N/A	N/A	N/A	N/A	N/A	$461K-64.3%	$1.3M+18.0%	$1.1M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	$102K-82.7%	$588K+59.5%	$369K
SG&A Expenses	$1.0M	N/A	$991K-45.0%	$1.8M+23.5%	$1.5M+152.5%	$578K-51.8%	$1.2M-11.2%	$1.3M
Operating Income	-$1.0M	N/A	-$991K+45.0%	-$1.8M-23.5%	-$1.5M-152.5%	-$578K+51.8%	-$1.2M+11.2%	-$1.3M
Interest Expense	$40K	N/A	$67K-24.6%	$89K+85.9%	$48K-77.7%	$214K+182.1%	$76K-36.5%	$119K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$987K	N/A	-$923K-117.0%	$5.4M+340.4%	-$2.3M+75.6%	-$9.3M-317.6%	-$2.2M-235.4%	-$662K
EPS (Diluted)	$-0.03	N/A	$-0.03+97.7%	$-1.29+86.2%	$-9.37	N/A	$-16.65-80.0%	$-9.25

PTPI Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$5.2M-51.4%	$10.6M-68.5%	$33.8M+4.2%	$32.4M-51.9%	$67.4M-3.5%	$69.9M
Current Assets	$5.2M-29.2%	$7.3M-64.2%	$20.4M+39.0%	$14.7M-52.0%	$30.5M+17.9%	$25.9M
Cash & Equivalents	$5.1M+198.9%	$1.7M-87.1%	$13.3M+41.5%	$9.4M-60.5%	$23.8M+39.1%	$17.1M
Inventory	N/A	$1.3M-16.2%	$1.6M-11.3%	$1.8M+249.3%	$520K-31.7%	$761K
Accounts Receivable	N/A	$416K-81.3%	$2.2M+5.5%	$2.1M-14.1%	$2.5M-52.4%	$5.2M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.3M-87.3%	$18.1M-15.1%	$21.3M+35.6%	$15.7M-50.6%	$31.8M-39.2%	$52.4M
Current Liabilities	$2.3M-87.3%	$18.0M+67.4%	$10.8M+52.4%	$7.1M-77.2%	$31.0M-26.1%	$41.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$2.9M+138.4%	-$7.5M-161.9%	$12.1M-27.7%	$16.7M-53.0%	$35.5M+103.5%	$17.5M
Retained Earnings	-$111.3M+1.7%	-$113.2M-14.5%	-$98.9M-9.0%	-$90.7M-28.3%	-$70.7M-14.6%	-$61.7M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$4.4M-14.9%	$5.2M-15.8%	$6.1M-17.1%	$7.4M-58.0%	$17.6M+65.5%	$10.6M-48.6%	$20.7M-17.8%	$25.2M
Current Assets	$4.4M-14.9%	$5.2M-15.8%	$6.1M-17.1%	$7.4M-48.9%	$14.5M+98.3%	$7.3M-32.0%	$10.7M-23.3%	$14.0M
Cash & Equivalents	$4.4M-15.3%	$5.1M-15.4%	$6.1M-17.1%	$7.3M-18.0%	$8.9M+419.7%	$1.7M-55.9%	$3.9M-48.0%	$7.5M
Inventory	N/A	N/A	N/A	N/A	N/A	$1.3M-4.0%	$1.4M-1.9%	$1.4M
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	$416K-78.6%	$1.9M+9.7%	$1.8M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.6M+14.4%	$2.3M-17.1%	$2.8M-6.3%	$2.9M-89.2%	$27.2M+50.2%	$18.1M+3.0%	$17.6M+10.0%	$16.0M
Current Liabilities	$2.6M+14.4%	$2.3M-17.1%	$2.8M-6.3%	$2.9M-89.1%	$27.1M+50.5%	$18.0M+43.5%	$12.6M+25.9%	$10.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$1.8M-38.3%	$2.9M-14.8%	$3.4M-24.3%	$4.4M+146.4%	-$9.6M-28.3%	-$7.5M-339.7%	$3.1M-61.4%	$8.1M
Retained Earnings	-$112.3M-0.9%	-$111.3M-0.3%	-$111.0M-0.8%	-$110.0M+4.7%	-$115.5M-2.0%	-$113.2M-8.9%	-$103.9M-2.2%	-$101.7M

PTPI Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$6.7M-158.7%	-$2.6M+65.9%	-$7.6M+40.4%	-$12.8M-7.9%	-$11.9M+22.5%	-$15.3M
Capital Expenditures	N/A	$25K	N/A	N/A	N/A	$5K
Free Cash Flow	N/A	-$2.6M	N/A	N/A	N/A	-$15.3M
Investing Cash Flow	N/A	-$25K	N/A	N/A	N/A	-$5K
Financing Cash Flow	$8.2M+216.6%	-$7.0M-160.7%	$11.5M+810.4%	-$1.6M-108.7%	$18.6M-38.7%	$30.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$784K+16.0%	-$934K+17.7%	-$1.1M+62.3%	-$3.0M-81.1%	-$1.7M-272.0%	$965K+225.2%	-$771K+53.6%	-$1.7M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	$5K	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	$960K	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	-$5K	N/A	N/A
Financing Cash Flow	$8.7M	$0+100.0%	-$117K+72.6%	-$428K-104.9%	$8.7M+860.7%	-$1.1M+58.7%	-$2.8M-41.7%	-$2.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

PTPI Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	76.3%+4.3pp	72.0%+10.2pp	61.8%-17.7pp	79.5%+21.9pp	57.7%
Operating Margin	N/A	-90.5%+143.4pp	-233.9%+98.5pp	-332.4%-101.3pp	-231.1%-50.3pp	-180.8%
Net Margin	N/A	-280.1%-139.9pp	-140.2%+194.2pp	-334.4%-219.3pp	-115.1%+100.3pp	-215.4%
Return on Equity	66.7%	N/A	-67.6%+52.3pp	-120.0%-94.7pp	-25.3%+92.6pp	-117.8%
Return on Assets	37.1%+171.7pp	-134.6%-110.5pp	-24.1%+37.6pp	-61.8%-48.5pp	-13.3%+16.1pp	-29.5%
Current Ratio	2.25+1.8	0.40-1.5	1.89-0.2	2.08+1.1	0.99+0.4	0.62
Debt-to-Equity	0.80+3.2	-2.42-4.2	1.77+0.8	0.94+0.0	0.90-2.1	3.00
FCF Margin	N/A	-51.4%	N/A	N/A	N/A	-160.2%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	63.5%-18.3pp	81.8%+4.9pp	76.8%
Operating Margin	N/A	N/A	N/A	N/A	N/A	-79.6%-3.7pp	-76.0%+18.9pp	-94.9%
Net Margin	N/A	N/A	N/A	N/A	N/A	-1278.4%-1137.5pp	-140.9%-94.3pp	-46.6%
Return on Equity	-55.7%	N/A	-27.4%-149.6pp	122.2%	N/A	N/A	-71.3%-63.1pp	-8.2%
Return on Assets	-22.5%	N/A	-15.0%-88.5pp	73.5%+86.3pp	-12.8%+74.4pp	-87.2%-76.5pp	-10.7%-8.1pp	-2.6%
Current Ratio	1.68-0.6	2.25+0.0	2.22-0.3	2.51+2.0	0.53+0.1	0.40-0.4	0.85-0.5	1.40
Debt-to-Equity	1.48+0.7	0.80-0.0	0.82+0.2	0.66+3.5	-2.84-0.4	-2.42-8.1	5.64+3.7	1.98
FCF Margin	N/A	N/A	N/A	N/A	N/A	132.3%	N/A	N/A

Similar Companies

Hemp HEMP

$1.2M

4Cable Tv Intern CATV

$1.1M

PLANET BASED FOODS GLOBAL INC PBFFF

$1.2M

Panacea Life Sciences Hldgs Inc PLSH

$3.0M

Ovation OVATF

$1.3M

Frequently Asked Questions

Is Petros Pharmaceuticals Inc profitable?

Yes, Petros Pharmaceuticals Inc (PTPI) reported a net income of $1.9M in fiscal year 2025.

What is Petros Pharmaceuticals Inc's return on equity (ROE)?

Petros Pharmaceuticals Inc (PTPI) has a return on equity of 66.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Petros Pharmaceuticals Inc's operating cash flow?

Petros Pharmaceuticals Inc (PTPI) generated -$6.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Petros Pharmaceuticals Inc's total assets?

Petros Pharmaceuticals Inc (PTPI) had $5.2M in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does Petros Pharmaceuticals Inc have outstanding?

Petros Pharmaceuticals Inc (PTPI) had 42M shares outstanding as of fiscal year 2025.

What is Petros Pharmaceuticals Inc's current ratio?

Petros Pharmaceuticals Inc (PTPI) had a current ratio of 2.25 as of fiscal year 2025, which is generally considered healthy.

What is Petros Pharmaceuticals Inc's debt-to-equity ratio?

Petros Pharmaceuticals Inc (PTPI) had a debt-to-equity ratio of 0.80 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Petros Pharmaceuticals Inc's return on assets (ROA)?

Petros Pharmaceuticals Inc (PTPI) had a return on assets of 37.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Petros Pharmaceuticals Inc's cash runway?

Based on fiscal year 2025 data, Petros Pharmaceuticals Inc (PTPI) had $5.1M in cash against an annual operating cash burn of $6.7M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Petros Pharmaceuticals Inc's Piotroski F-Score?

Petros Pharmaceuticals Inc (PTPI) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Petros Pharmaceuticals Inc's earnings high quality?

Petros Pharmaceuticals Inc (PTPI) has an earnings quality ratio of -3.52x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Petros Pharmaceuticals Inc cover its interest payments?

Petros Pharmaceuticals Inc (PTPI) has an interest coverage ratio of -18.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.